"LeapStack Biology" completes over 50 million yuan in Series A+ financing.

Recently, Shanghai Yupai Life Sciences Co., Ltd. announced the completion of over 50 million yuan in Series A+ financing, which was jointly completed by PanLin Capital, QuanCun Venture Capital, and Waigaoqiao Private Equity Fund. This round of funding will be used to accelerate the clinical trials of the company's general-purpose cell drugs for epilepsy and Parkinson's disease, and further deepen the scale development and industrialization of innovative cell therapy drugs.